Peregrine Pharmaceuticals (NASDAQ:PPHM)

EnigmaDude (96.57) Submitted: 9/24/2012 11:24:19 AM

Recs: 2

Are you for real? First you try to convince everyone that this stock is a winner and now you think that biotech companies don't report "unreliable" data! Welcome to the real world...

TruffelPig (< 20) Submitted: 9/25/2012 7:38:31 PM

Recs: 0

The stock was a winner when the data were still reported as if they were valid. This is by far worse than a Phase III trial being sugar coated. At this point there are no data really of this Phase II trial anymore. Zero, nothing, zilch. So we are back in June or May really and at that point I was not supporting PPHM. The data they reported seemed really outstanding. I am obviously not happy about this. It would be stupid, however, now to claim that nothing has changed. Roth Capital did reduce the price target from $9 to 70 cents for a reason after this came out. That was the price target the company had before the run up started.

Anyhow, one can learn lessons from this in particular that one trick ponies are extremely dangerous investments.

To the unreliable part: actually they should not because it will backfire and most trials are run pretty well. I am a bit concerned frequently about meta analysis and the such.

Anyhow, good luck to you.

MyStockHasRabies (78.84) Submitted: 10/11/2012 4:17:33 AM

Recs: 0

3 arms...docetaxel + placebo...docetaxel+1 mg bavi...docetaxel+3 mg bavi...problem was only in the bavi arms...do the math yourself...therefor 2x life expectancy did occur with bavi, but dosage is uncertain. Pretty phenomenal if you ask me. The placebo didn't double life expectency & docetaxel doses were constant across the board. So this leaves ______ (fill in the blank) to be the component of the trial to increase life expectancy. If you can't fill in the blank stay away from stocks in general. Erroneous data is extremely common in biotech. If ya can't take the heat, stay outta the kitchen. GLTA